Posluma
Payments companies reported to CMS as associated with Posluma. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Posluma, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Posluma
These are the largest totals companies reported as associated with Posluma. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Sean Collins | Washington, DC | Radiation Oncology | $77,975.81 |
| Hossein Jadvar | Los Angeles, CA | Nuclear Medicine | $47,654.99 |
| Phillip Kuo | Duarte, CA | Diagnostic Radiology | $36,013.57 |
| Kristina Hawk | Stanford, CA | Nuclear Radiology | $34,873.05 |
| Kevin Berger | Annapolis, MD | Diagnostic Radiology | $20,385.69 |
| Ephraim Parent | Jacksonville, FL | Nuclear Medicine | $18,866.26 |
| Louis Mazzarelli | New York, NY | Diagnostic Radiology | $14,010.07 |
| Ashley Ross | Chicago, IL | Urology | $13,711.21 |
| Jan Basile | Charleston, SC | Internal Medicine | $13,300.00 |
| Phillip Koo | Aurora, CO | Diagnostic Radiology | $11,637.37 |
Prescribed Posluma?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.